EGFR and neoplasm: Nine factors were considered, including icotinib treatment, gender, age (≤78 years vs. >78 years), tumor length (<5 cm vs. ≥5 cm), tumor location (upper vs. middle vs. lower), clinical stage (II vs. III, AJCC 7th), EGFR expression ((+, Low) vs. (++~+++, High)) (Figure S1)), weight loss of more than 5% within 6 months, and ECOG score.